[Somatostatin in the treatment of pancreatic diseases]
- PMID: 12063869
[Somatostatin in the treatment of pancreatic diseases]
Abstract
Somatostatin and its synthetic analogues have important physiological roles in human. These compounds antagonize the endocrine and exocrine secretion of pancreas, which provide theoretical ground for their use in patients with pancreatic diseases. For a quarter of a century many researchers have investigated the effect of somatostatin and octreotide in animal models of experimental pancreatitis and in patients with acute pancreatitis, and in those with complications of pancreatic operations, fistulas and pseudocysts. In most of these studies the use of synthetic octreotide with longer duration proved to be more efficient. In experimental and acute pancreatitis somatostatin and octreotide were less effective than expected, however, they proved to be helpful in preventing complications of pancreatic operations and in the therapy of fistulas and pseudocysts.
Similar articles
-
Use of somatostatin and its long-acting analogue, octreotide, in the treatment of pancreatic diseases.Aliment Pharmacol Ther. 1995 Oct;9(5):581-3. Aliment Pharmacol Ther. 1995. PMID: 8580282 No abstract available.
-
Effect of the somatostatin analogue octreotide on experimental pancreatitis in rats.J Surg Res. 1996 May;62(2):201-6. doi: 10.1006/jsre.1996.0196. J Surg Res. 1996. PMID: 8632640
-
Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results.JOP. 2003 Jan;4(1):33-40. JOP. 2003. PMID: 12555014 Review.
-
[Efficacy of somatostatin and its analogues in the treatment of acute pancreatitis: clinical retrospective study].G Chir. 2001 Apr;22(4):139-49. G Chir. 2001. PMID: 11370223 Italian.
-
Conservative treatment of acute pancreatitis: the use of somatostatin.Hepatogastroenterology. 1992 Oct;39(5):466-9. Hepatogastroenterology. 1992. PMID: 1360937 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical